New drug tested for Tough-to-Treat blood cancers
NCT ID NCT05673460
Summary
This study was the first to test the safety and early effects of an experimental drug called nemtabrutinib in Japanese adults with advanced B-cell blood cancers. It involved a small group of participants whose previous treatments had stopped working. The main goal was to find a safe dose and see how the body processes the drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MATURE B-CELL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chiba Cancer Center ( Site 0005)
Chiba, 260-8717, Japan
-
Kindai University Hospital ( Site 0006)
Sayama, Osaka, 589-8511, Japan
-
Kyushu University Hospital ( Site 0008)
Fukuoka, 812-8582, Japan
-
Nagoya University Hospital ( Site 0003)
Nagoya, Aichi-ken, 466-8560, Japan
-
National Cancer Center Hospital East ( Site 0002)
Kashiwa, Chiba, 2778577, Japan
-
Okayama University Hospital ( Site 0007)
Okayama, 700-8558, Japan
-
Yamagata University Hospital ( Site 0001)
Yamagata, 990-9585, Japan
Conditions
Explore the condition pages connected to this study.